{"id":"nvx-cov2705-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Myalgia"},{"rate":"25-35","effect":"Headache"},{"rate":"10-20","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses recombinant nanoparticle technology to display stabilized spike proteins from SARS-CoV-2 variants, combined with Matrix-M adjuvant to enhance immunogenicity. This approach triggers both humoral (antibody) and cellular (T-cell) immune responses without using live virus or viral vectors. The vaccine is designed to provide protection against emerging COVID-19 variants, particularly Omicron-derived strains.","oneSentence":"NVX-CoV2705 is a recombinant protein subunit vaccine that presents SARS-CoV-2 spike protein antigens to stimulate adaptive immune responses against COVID-19 variants.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:45.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults (variant-specific formulation)"}]},"trialDetails":[{"nctId":"NCT07051031","phase":"PHASE4","title":"COVID-19 Reactogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcel Curlin","startDate":"2025-10-01","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT07079670","phase":"PHASE3","title":"Safety and Immunogenicity of NVX-CoV2705","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-10-09","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":676},{"nctId":"NCT07086222","phase":"PHASE4","title":"Efficacy and Safety of NVX-CoV2705","status":"NOT_YET_RECRUITING","sponsor":"Novavax","startDate":"2025-11-10","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":6500},{"nctId":"NCT06409663","phase":"PHASE3","title":"A Strain Change Study for SARS-CoV-2 rS Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2024-10-14","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 Infection","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SARS-CoV-2 rS"],"phase":"phase_3","status":"active","brandName":"NVX-CoV2705 Vaccine","genericName":"NVX-CoV2705 Vaccine","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"NVX-CoV2705 is a recombinant protein subunit vaccine that presents SARS-CoV-2 spike protein antigens to stimulate adaptive immune responses against COVID-19 variants. Used for COVID-19 prevention in adults (variant-specific formulation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}